Advanced Optics Electronics Inc. BioModa Holding Announces Technology Tested For Commercial Use In Foreign Markets.ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Feb. 16, 1999-BioModa Inc, announced on Feb. 8 it is now prepared to begin "Opinion Leader" testing of its TCPP TCPP Turbo C++ (Programming Language) TCPP Traitements Composites Poudres et Process (Composite Powder Treatments and Processes) TCPP Texas Commercial Package Policy Diagnostic for abnormal lung cells. BioModa's tests will be conducted in cooperation with foreign partners in Korea, China, India, Australia and Romania. "Commercial use of clinical tests in these countries represents a significant milestone reached by our research staff," stated BioModa's President, Ari Ma'ayan. "We have successfully developed strong partner relationships in Korea, China, India, Australia and Romania. "These potential markets include more than two billion people and over $500 million in estimated revenues for lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. testing over the next 3 years." "From a humanitarian standpoint, lung cancer has reached epidemic proportions in these countries and, consequently, we are able to obtain unprecedented access through government officials. In China alone, more than one million people die of lung cancer annually, and that number continues to rise dramatically." The BioModa TCPP diagnostic can detect pre-cancerous changes in the cells lining a person's lungs several years prior to the onset of invasive carcinoma. "Obviously, earlier detection is the focus of our technology," said Jeff Garwin, MD, PhD, BioModa's chief technical officer. "We believe our test will provide the means for saving millions of lives worldwide." The test materials are currently available in the US in a "bulk" format and will soon be available in a "kit" format. Upon completion of the test kit and commercial distribution of same, the company plans to follow up the TCPP lung test with additional diagnostics related to cancer in other organs of the body. In addition to their patented lung cancer test, BioModa is working on diagnostic imaging and radio pharmaceutical therapeutic for lung cancer and other cancers. About the Company BioModa Inc. is an emerging biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. company specializing in breakthrough cancer diagnostics and therapy. BioModa Inc. owns a patented lung cancer test capable of detecting lung cancer up to six years earlier than any other available test and recently received efficacy confirmation from double-blind studies double-blind study, n experimental technique in clinical research in which neither the researcher nor the patient knows whether the treatment administered is considered inactive (placebo) or active (medicinal). conducted by LungCheck(R) Inc. of Scottsdale, AZ. BioModa's technology also encompasses the treatment of lung cancer. BioModa's prominent research team has included world-leading cytopathologists, Dr. Geno Saccomanno of St. Mary's Hospital and Medical Center, Dr. Jim Mulshine of the National Cancer Institute and the late Dr. John Frost John Frost may refer to:
Also currently involved in BioModa's research is Dr. L. Edward Ellinwood, a nationally recognized pharmacologist from St. Mary's Hospital and Los Alamos National Laboratories Los Alamos National Laboratory (LANL) (previously known at various times as Site Y, Los Alamos Laboratory, and Los Alamos Scientific Laboratory) is a United States Department of Energy (DOE) national laboratory, managed and operated by Los Alamos National . BioModa Inc. has conducted the bulk of its research through grants, private and public investments and through an equity investment from Advanced Optics Electronics Inc.(OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:ADOT ADOT Arizona Department Of Transportation ADOT Alaska Department of Transportation ADOT Fédération des Associations pour le Don d'Organes et de Tissus Humains ADOT Active Duty Other Than Training ADOT Automatic Digital Optical Tracker ADOT Advanced Display Optimization Tools ). BioModa is currently negotiating major financing with several of the largest investment banking firms in the country. Advanced Optics Electronics Inc. currently owns 22.8 percent of BioModa Inc. with an option, if fully exercised which allows Advanced Optics Electronics Inc. position to move to approximately 26.5 percent of BioModa Inc. Advanced Optics Company Information Advanced Optics Electronics Inc. (OTC BB:ADOT) is a developer of patented electronic display technology, utilizing ADOT's proprietary SLM See service level management system and spatial light modulator. (Spatial Light Modulator (1) A matrix of movable mirrors used to reflect a digital image to the viewer. See DLP. (2) A matrix of shutters that represents a page of binary data. It is used to modulate a laser beam for holographic storage. See holographic storage. ) light valve. This industry-leading technology can be utilized in many diverse fields including the production of "television quality" advertising billboards, medical testing equipment, military displays, computer monitors and high definition video transmission. Shareholder Relations Note ADOT will promptly respond to all requests for information from shareholders and the general public, shareholders will receive priority response. All such requests must be sent to ADOT via FAX: 505/858-1871 or U.S. Mail to 8301 Washington Ave. Building 4, Albuquerque, NM 87113. All such requests must include the Name, Daytime Fax (if available) and Street Address as box numbers cannot be accepted. This News Release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. with respect to the results of operations and business of the company that involves risk and uncertainties. The company's actual future results could materially differ from those discussed. Risks and uncertainties of the company will be detailed from time to time in the company's periodic reports to be filed with the Securities and Exchange Commission. Contact Advanced Optics Electronics Inc. at 505/797-7878 or visit their Web site at www.adot.org. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion